Cancer Therapy by Nanomedicine
Currently most used drug therapies in the fight against tumors are based on antibodies or nanodimensional systems (nanomedicine) directed toward specific molecular targets in order to counter the metabolic processes of tumor proliferation or induce the death of cancer cells. The use of such therapies has encountered significant limitations, because of the resistance to transport in the tumor microenvironment that reduces the diffusion of the drug and restricts the distribution within the stroma and cancer cells. The purpose of the project is to study new combined therapeutic strategies which will increase the volume of distribution and the amount of anticancer drugs selectively in the tumor tissue, due to variation in the pathophysiological state. To this end, the project is divided with a series of preclinical testing by making use of optical imaging techniques using fluorescent contrast agents for testing the permeability of tissues from nanoparticles and monoclonal antibodies. The validation of the results will be obtained through the analysis of histological images of immunofluorescence for the expression and characterization of the biomarkers associated with the action of the therapeutic and the analysis of the volume of distribution of contrast agents in tumor tissue.